3 recruiting, 1 active not recruiting, 1 unknown, 1 withdrawn. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 3, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
Follow Angiosarcoma: new trials by email Literature Review of Angiosarcoma trials Research Report on Angiosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors AGX101 - Cancer, Advanced Cancer | Phase 1 | Recruiting | Angiex, Inc. | 80 | 2024-07-22 | 2026-09-09 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma Paclitaxel, mRNA plus Lysate-loaded Dendritic Cell Vaccine, PEGYLATED-INTERFERON ALPHA-2A - Angiosarcoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2024-03-22 | 2026-02-13 | |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer MQ719, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 56 | 2023-05-04 | 2026-08-12 |
| Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer Botensilimab, Balstilimab - Advanced Cancer, Angiosarcoma | Phase 1 | Active not recruiting | Agenus Inc. | 499 | 2019-03-20 | 2026-03-30 |
| Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO) PROPRANOLOL - Angiosarcoma | Phase 1 / Phase 2 | Unknown | Assistance Publique Hopitaux De Marseille | 24 | 2016-05-01 | 2016-04-11 |
Hemangiosarcoma (6) · Neoplasm Metastasis (2) · Neoplasms (2) · Prostatic Neoplasms (2) · Adenocarcinoma, Sebaceous (1) · Breast Neoplasms (1) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Skin Appendage (1) · Carcinoma, Squamous Cell (1) · Chondrosarcoma, Extraskeletal Myxoid (1) · Colorectal Neoplasms (1) · Dermatofibrosarcoma (1) · Disorders of Sex Development (1)
Neoplasms by Histologic Type (6) · Neoplasms, Connective and Soft Tissue (6) · Neoplasms, Vascular Tissue (6) · Sarcoma (5) · Neoplasms (4) · Endocrine System Diseases (3) · Male Urogenital Diseases (3) · Neoplasms by Site (3) · Urogenital Diseases (3) · Endocrine Gland Neoplasms (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2)
Doxorubicin (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Ifosfamide (1) · Ipilimumab (1) · Paclitaxel (1) · Propranolol (1) · Proton Therapy (1) · RNA, Messenger (1) · balstilimab (1) · pazopanib (1) · peginterferon alfa-2a (1) · pembrolizumab (1) · selinexor (1) · spartalizumab (1)
Agenus Inc. (1) · Angiex, Inc. (1) · Assistance Publique Hopitaux De Marseille (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · St. Jude Children's Research Hospital (1)
United States (4) · France (1) · United Kingdom (1)
Glen Weiss, MD (1) · Jessica Gartrell, MD (1) · Lara Dunn, MD (1) · Urielle Desalbres (1) · Vinod Ravi, MD (1)
PMID 38871975, PMID 39869830, PMID 41502912
2015 (1)